CliffBio
small molecule

SUMATRIPTAN

SUMATRIPTAN

Loss of exclusivity—loss of exclusivity
CompanyCipla →See this company's full patent-cliff portfolio

Drug detail

Brand nameSUMATRIPTAN
Active ingredientSUMATRIPTAN
Strength20MG/SPRAY
Dosage formSPRAY
RouteNASAL
ModalitySmall molecule
FDA approvalFebruary 2021
Marketing statusRX

More from Cipla

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.

SUMATRIPTAN patent cliff — loss of exclusivity — | CliffBio